Dyadic International, Inc. (DYAI)
Automate Your Wheel Strategy on DYAI
With Tiblio's Option Bot, you can configure your own wheel strategy including DYAI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DYAI
- Rev/Share 0.1189
- Book/Share 0.0309
- PB 30.3523
- Debt/Equity 5.4839
- CurrentRatio 3.9779
- ROIC -0.972
- MktCap 28225077.0
- FreeCF/Share -0.161
- PFCF -5.8661
- PE -4.8109
- Debt/Assets 0.6416
- DivYield 0
- ROE -2.3369
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
No ratings available. |
News
Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth markets Leadership team realigned in order to enable execution of ancillary protein strategy Dyadic is well positioned to seize on geopolitical tailwinds driving reshoring/friendshoring of biomanufacturing supply chains to the United States and allies abroad JUPITER, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI) today announced a leadership change as part of its ongoing strategic shift to evolve into a revenue-generating provider of ancillary recombinant protein products supporting the life sciences, nutrition, and industrial markets.
Read More
Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025.
Read More
Dyadic to Present at World Vaccine Congress | Washington
Published: April 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company that utilizes its microbial production platforms to develop commercial cell lines for the efficient large-scale manufacture of proteins for use in human and animal reagents, vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications today announced that Mark Emalfarb, Chief Executive Officer, will present at the 2025 World Vaccine Congress in Washington, D.C.
Read More
Dyadic International, Inc. (DYAI) Q4 2024 Earnings Call Transcript
Published: March 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Dyadic International, Inc. (NASDAQ:DYAI ) Q4 2024 Earnings Conference Call March 26, 2025 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President & Chief Executive Officer Joe Hazelton - Chief Operating Officer Conference Call Participants John Vandermosten - Zacks Small Capital Research Vernon Bernardino - HC Wainwright Dick Williams - Williams Resource Group Operator Good evening and welcome to Dyadic International's Year-End 2024 Conference Call. Currently, all participants are in a listen-only mode.
Read More
About Dyadic International, Inc. (DYAI)
- IPO Date 2008-01-16
- Website https://www.dyadic.com
- Industry Biotechnology
- CEO Mr. Mark A. Emalfarb
- Employees 6